Connection

SANJAY MATHEW to Anxiety Disorders

This is a "connection" page, showing publications SANJAY MATHEW has written about Anxiety Disorders.
Connection Strength

3.504
  1. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019 Nov; 28(11):1003-1012.
    View in: PubMed
    Score: 0.440
  2. Neurobiology of the dorsolateral prefrontal cortex in GAD: Aberrant neurometabolic correlation to hippocampus and relationship to anxiety sensitivity and IQ. J Affect Disord. 2018 03 15; 229:1-13.
    View in: PubMed
    Score: 0.387
  3. Impact of childhood emotional abuse on neocortical neurometabolites and complex emotional processing in patients with generalized anxiety disorder. J Affect Disord. 2016 Jan 15; 190:414-423.
    View in: PubMed
    Score: 0.333
  4. Reduced hippocampal N-acetyl-aspartate (NAA) as a biomarker for overweight. Neuroimage Clin. 2014; 4:326-35.
    View in: PubMed
    Score: 0.295
  5. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed. 2009 Apr; 22(3):251-8.
    View in: PubMed
    Score: 0.212
  6. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study. Clin Ther. 2008 Sep; 30(9):1658-66.
    View in: PubMed
    Score: 0.203
  7. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet C Semin Med Genet. 2008 May 15; 148C(2):89-98.
    View in: PubMed
    Score: 0.199
  8. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry. 2008 May 01; 63(9):891-8.
    View in: PubMed
    Score: 0.192
  9. Glutamate and anxiety disorders. Curr Psychiatry Rep. 2007 Aug; 9(4):278-83.
    View in: PubMed
    Score: 0.188
  10. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry. 2005 Dec; 162(12):2379-81.
    View in: PubMed
    Score: 0.168
  11. Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study. Am J Psychiatry. 2004 Jun; 161(6):1119-21.
    View in: PubMed
    Score: 0.151
  12. Trajectories of self-reported sleep disturbance across inpatient psychiatric treatment predict clinical outcome in comorbid major depressive disorder and generalized anxiety disorder. J Affect Disord. 2019 05 15; 251:248-255.
    View in: PubMed
    Score: 0.106
  13. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243.
    View in: PubMed
    Score: 0.104
  14. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017 Apr 01; 74(4):399-405.
    View in: PubMed
    Score: 0.092
  15. Riluzole effect on occipital cortex: a structural and spectroscopy pilot study. Neurosci Lett. 2012 Nov 14; 530(1):103-7.
    View in: PubMed
    Score: 0.067
  16. A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD. Eur Neuropsychopharmacol. 2013 Apr; 23(4):276-84.
    View in: PubMed
    Score: 0.066
  17. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs. 2010 Aug; 24(8):669-93.
    View in: PubMed
    Score: 0.058
  18. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008 Apr; 28(2):235-9.
    View in: PubMed
    Score: 0.049
  19. Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med. 2006 Nov; 73(7):941-9.
    View in: PubMed
    Score: 0.045
  20. Decreased choline and creatine concentrations in centrum semiovale in patients with generalized anxiety disorder: relationship to IQ and early trauma. Psychiatry Res. 2006 Jun 30; 147(1):27-39.
    View in: PubMed
    Score: 0.044
  21. Molecular targets in the treatment of anxiety. Biol Psychiatry. 2002 Nov 15; 52(10):1008-30.
    View in: PubMed
    Score: 0.034
  22. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology. 2020 09; 45(10):1656-1663.
    View in: PubMed
    Score: 0.029
  23. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.
    View in: PubMed
    Score: 0.028
  24. The role of early life stress in development of the anterior limb of the internal capsule in nonhuman primates. Neurosci Lett. 2010 Aug 16; 480(2):93-6.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.